More than 37% of shareholders vote against or abstain on vote including £9.4m pay package for pharmaceutical firm’s boss
AstraZeneca has been rocked by one of the biggest shareholder revolts over executive pay this year, after more than a third of investors failed to back the pharmaceutical company’s remuneration report.
More than 37% of shareholders voted against or abstained at the company’s annual shareholder meeting in London on Friday in the second rebuke by investors for the company in as many years.